Free Trial

Jyong Biotech (MENS) Competitors

Jyong Biotech logo
$62.00 +2.47 (+4.15%)
As of 09/23/2025 04:00 PM Eastern

MENS vs. GMAB, SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, ELAN, and VRNA

Should you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

Jyong Biotech vs. Its Competitors

Genmab A/S (NASDAQ:GMAB) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Genmab A/S currently has a consensus target price of $40.00, suggesting a potential upside of 39.23%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.73
Jyong Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Genmab A/S has a net margin of 37.53% compared to Jyong Biotech's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Jyong Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S37.53% 21.03% 16.98%
Jyong Biotech N/A N/A N/A

In the previous week, Jyong Biotech had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Jyong Biotech and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.62 beat Jyong Biotech's score of 0.53 indicating that Genmab A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jyong Biotech
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genmab A/S has higher revenue and earnings than Jyong Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.12B5.90$1.14B$1.9914.44
Jyong BiotechN/AN/AN/AN/AN/A

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Genmab A/S beats Jyong Biotech on 11 of the 12 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MENS vs. The Competition

MetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$4.53B$873.85M$2.54B$10.50B
Dividend YieldN/A4.84%2.49%4.57%
P/E RatioN/A1.2126.4526.62
Price / SalesN/A116.80218.8291.77
Price / CashN/A17.6451.2461.85
Price / BookN/A6.4633.216.45
Net IncomeN/A-$5.56M$14.12M$271.57M
7 Day Performance15.43%0.53%0.62%2.61%
1 Month Performance34.78%5.75%3.72%7.28%
1 Year PerformanceN/A25.85%70.48%29.60%

Jyong Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MENS
Jyong Biotech
N/A$62.00
+4.1%
N/AN/A$4.53BN/A0.0031Gap Down
High Trading Volume
GMAB
Genmab A/S
3.5686 of 5 stars
$27.99
+0.6%
$39.25
+40.2%
+19.0%$17.85B$3.12B16.272,682Analyst Upgrade
SMMT
Summit Therapeutics
3.1619 of 5 stars
$18.94
flat
$33.79
+78.4%
-12.6%$14.07B$700K-18.75110
RDY
Dr. Reddy's Laboratories
2.7472 of 5 stars
$14.64
-0.2%
$16.95
+15.8%
-8.9%$12.24B$3.81B22.1727,811Positive News
ASND
Ascendis Pharma A/S
2.9825 of 5 stars
$194.62
-0.5%
$244.36
+25.6%
+32.3%$11.97B$393.54M-37.721,017Positive News
VTRS
Viatris
1.2988 of 5 stars
$9.60
-3.6%
$10.40
+8.3%
-16.3%$11.61B$14.74B-3.3132,000High Trading Volume
QGEN
QIAGEN
4.3595 of 5 stars
$45.39
+0.2%
$49.69
+9.5%
+5.5%$10.07B$1.98B26.825,765
BBIO
BridgeBio Pharma
4.4959 of 5 stars
$51.47
+0.5%
$63.94
+24.2%
+102.8%$9.79B$221.90M0.00400
ROIV
Roivant Sciences
3.4248 of 5 stars
$13.95
-0.9%
$17.67
+26.6%
+23.9%$9.61B$29.05M0.00860Trending News
Insider Trade
Analyst Revision
ELAN
Elanco Animal Health
2.5914 of 5 stars
$18.63
+0.5%
$17.33
-6.9%
+28.5%$9.21B$4.44B21.669,000
VRNA
Verona Pharma PLC American Depositary Share
2.0411 of 5 stars
$106.37
-0.1%
$109.00
+2.5%
+259.0%$9.17B$42.28M-107.4430Positive News

Related Companies and Tools


This page (NASDAQ:MENS) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners